secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007032
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx amends Hercules loan: no prepayment penalty, cash covenant cut to $2.25M, $7.5M repaid
--------------------------------------------------------------------------------

- Prepayment premium eliminated (was 1-3%); company may prepay anytime without fee.
- Interest-only period extended to Sep 1, 2023 (from Apr 1, 2023); further extension conditional on $35M equity raise.
- Minimum cash covenant reduced from $6.3M-$10M to $2.25M; drops to $0 if $20M raised by May 31, 2023.
- Company repaid $7.5M of principal as condition, reducing outstanding Term Loan to $5.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000095017023007032/0000950170-23-007032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000095017023007032/elox-20230307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer